Publicacións (30) Publicacións de Joaquín Casal Rubio

2023

  1. PD-1/PD-L1 Inhibitors as Monotherapy in the First-Line Treatment of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression: An Expert Position Statement

    Journal of Clinical Medicine, Vol. 12, Núm. 15

2022

  1. Determination of essential biomarkers in lung cancer: a real-world data study in Spain with demographic, clinical, epidemiological and pathological characteristics

    BMC Cancer, Vol. 22, Núm. 1

  2. Overall Survival and Biomarker Analysis of Neoadjuvant Nivolumab Plus Chemotherapy in Operable Stage IIIA Non-Small-Cell Lung Cancer (NADIM phase II trial)

    Journal of Clinical Oncology, Vol. 71

  3. Real-world data with afatinib in Spanish patients with treatment-naïve non-small-cell lung cancer harboring exon 19 deletions in epidermal growth factor receptor (Del19 EGFR): Clinical experience of the Galician Lung Cancer Group

    Cancer Treatment and Research Communications, Vol. 33

  4. Utility of Genomic Platforms in Treatment Decisions in Axilla-Positive Breast Cancer

    Clinical Breast Cancer, Vol. 22, Núm. 7, pp. 634-641

2021

  1. Efficacy and safety of Nivolumab in older patients with pretreated lung cancer: A subgroup analysis of the Galician lung cancer group

    Journal of Geriatric Oncology, Vol. 12, Núm. 3, pp. 410-415

  2. Prognostic model of long-term advanced stage (IIIB-IV) EGFR mutated non-small cell lung cancer (NSCLC) survivors using real-life data

    BMC Cancer, Vol. 21, Núm. 1

2020

  1. PD-(L)1 inhibitors in combination with chemotherapy as first-line treatment for non-small-cell lung cancer: A pairwise meta-analysis

    Journal of Clinical Medicine, Vol. 9, Núm. 7, pp. 1-13

2018

  1. Real world data of nivolumab for previously treated non-small cell lung cancer patients: A Galician lung cancer group clinical experience

    Translational Lung Cancer Research, Vol. 7, Núm. 3, pp. 404-415

2016

  1. EGFR testing and clinical management of advanced NSCLC: A galician lung cancer group study (GGCP 048-10)

    Cancer Management and Research, Vol. 8, pp. 11-20

2015

  1. Erlotinib as second-line therapy for patients with advanced non-small-cell lung cancer and wild-type EGFR tumors

    Journal of Analytical Oncology, Vol. 4, Núm. 3, pp. 94-101

  2. Phase II study of first-line biweekly docetaxel and cisplatin combination chemotherapy in advanced gastric cancer

    Cancer Chemotherapy and Pharmacology, Vol. 76, Núm. 4, pp. 731-737

2014

  1. A phase II trial of erlotinib as maintenance treatment after concurrent chemoradiotherapy in stage III non-small-cell lung cancer (NSCLC): A Galician Lung Cancer Group (GGCP) study

    Cancer Chemotherapy and Pharmacology, Vol. 73, Núm. 3, pp. 451-457

  2. Final results of a phase II study of paclitaxel, bevacizumab, and gemcitabine as first-line therapy for patients with HER2-negative metastatic breast cancer

    Clinical and Translational Oncology, Vol. 17, Núm. 2, pp. 160-166

  3. Full-dose cisplatin and oral vinorelbine concomitant with radiotherapy in unresectable stage III non-small cell lung cancer: A multi-center phase II study

    Anticancer Research, Vol. 34, Núm. 4, pp. 1959-1966

  4. Second-line treatment in advanced non-small-cell lung cancer in the epidermal growth factor receptor wild-type population: Review of patient profile

    Anti-Cancer Drugs, Vol. 25, Núm. 4, pp. 368-374

2013

  1. Biweekly XELOX (capecitabine and oxaliplatin) as first-line treatment in elderly patients with metastatic colorectal cancer

    Journal of Geriatric Oncology, Vol. 4, Núm. 2, pp. 114-121

2012

  1. First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

    Expert Opinion on Pharmacotherapy, Vol. 13, Núm. 10, pp. 1389-1396

2009

  1. A phase II randomized trial of gemcitabine-docetaxel versus gemcitabine-cisplatin in patients with advanced non-small cell lung carcinoma

    Cancer Chemotherapy and Pharmacology, Vol. 64, Núm. 2, pp. 379-384

2007

  1. Biweekly administration of docetaxel and vinorelbine as second-line chemotherapy for patients with stage IIIB and IV non-small cell lung cancer: A phase II study of the Galician Lung Cancer Group (GGCP 013-02)

    Anti-Cancer Drugs, Vol. 18, Núm. 10, pp. 1201-1206